– Company also Secures Follow-on Order from Existing Contract Research Customer for Adoptive Cell Therapy (CAR T) Application –
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that it received orders for its linear DNA to be evaluated in an RNA vaccine and Adeno-Associated Virus (AAV) production from two new contract research customers, respectively. The Company also received a follow-on order for linear DNA from an existing contract research customer for a preclinical CAR T therapy. The follow-on order marks the third order from the existing customer for use across multiple applications. All orders are to be shipped by the end of calendar 2020.
Applied DNA’s unique large-scale PCR production of linear DNA is made capable by its LinearDNA™ platform, a proprietary process that enables large, gram-scale production of single- or double-stranded DNA for diagnostics; therapeutics, such